June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Changes in Visual Function during 2-year Follow-up after UF-021 Therapy for Retinitis Pigmentosa
Author Affiliations & Notes
  • Yosuke Nakamura
    Chiba Universitiy Graduate School of Medicine, Chiba, Japan
  • Akira Hagiwara
    Chiba Universitiy Graduate School of Medicine, Chiba, Japan
  • Ken Kumagai
    Chiba Universitiy Graduate School of Medicine, Chiba, Japan
  • Shuichi Yamamoto
    Chiba Universitiy Graduate School of Medicine, Chiba, Japan
  • Footnotes
    Commercial Relationships Yosuke Nakamura, None; Akira Hagiwara, None; Ken Kumagai, None; Shuichi Yamamoto, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 673. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yosuke Nakamura, Akira Hagiwara, Ken Kumagai, Shuichi Yamamoto; Changes in Visual Function during 2-year Follow-up after UF-021 Therapy for Retinitis Pigmentosa. Invest. Ophthalmol. Vis. Sci. 2013;54(15):673. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: We have reported that topical 0.15% unoprostone ophthalmic solution (UF-021) resulted in a dose-dependent improvement in the central retinal sensitivity in patients with retinitis pigmentosa (RP). The purpose of this study was to determine the changes in visual function 2-year after the end of the UF-021 treatment.

Methods: We studied 22 eyes of 22 RP patients who had been part of the origin 24-week clinical trial of UF-021. These patients had been randomly assigned to one of the three double-blind treatments: high dose (H, two drops/dose; n=6), low dose (L, one drop/dose; n=8), and placebo (P, n=8). The therapy was terminated in all the patients after the 24 week trial. We examined the mean retinal sensitivity of four central sites using the Humphrey Field Analyzer (HFA) 10-2 program, mean deviation (MD value), and the BCVA at the start and end of the clinical trial. These parameters were also measured 120 weeks after the completion of the trial.

Results: We studied 22 eyes of 22 RP patients who had been part of the origin 24-week clinical trial of UF-021. These patients had been randomly assigned to one of the three double-blind treatments: high dose (H, two drops/dose; n=6), low dose (L, one drop/dose; n=8), and placebo (P, n=8). The therapy was terminated in all the patients after the 24 week trial. We examined the mean retinal sensitivity of four central sites using the Humphrey Field Analyzer (HFA) 10-2 program, mean deviation (MD value), and the BCVA at the start and end of the clinical trial. These parameters were also measured 120 weeks after the completion of the trial.

Conclusions: The retinal sensitivity in the H group was maintained even 2 years after the UF-021 therapy was stopped. This suggests a long-term preservation of the visual sensitivity by UF-021.

Keywords: 688 retina • 615 neuroprotection • 758 visual fields  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×